Get the latest news, insights, and market updates on ATYR (aTyr Pharma, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis
Study did not meet primary endpoint in change from baseline in mean daily oral corticosteroid (OCS) dose at week 48, although clinical benefit for efzofitimod observed across multiple study parameters. 52.6% of patients treated with 5.0 mg/kg efzofitimod achieved complete steroid withdrawal at week 48 vs 40.2% on placebo (p=0.0919). Clinical improvement in King’s Sarcoidosis Questionnaire (KSQ)-Lung score at week 48 observed in the 5.0 mg/kg efzofitimod treatment group vs placebo (p=0.0479). Gre Sep 15, 2025 - $ATYR
Lead Therapy Trial Fuels aTyr Pharma’s (ATYR) Promising Upside, Leerink Stays Bullish
aTyr Pharma Inc. (NASDAQ:ATYR) is one of the best multibagger stocks to invest in right now. On August 22, Leerink Partners’ Faisal Khurshid reiterated a Buy rating on aTyr Pharma Inc. (NASDAQ:ATYR) with a $16 price target. His view reflects optimism around the EFZO-FIT trial, which is testing efzofitimod as a potential treatment for pulmonary sarcoidosis. […] Sep 11, 2025 - $ATYR
Jefferies Raises Price Target for aTyr Pharma (ATYR) Ahead of Study Results
aTyr Pharma, Inc. (NASDAQ:ATYR) is one of the Top 10 Stocks Under $10 That Could Triple. On August 22, Jefferies increased its price target for aTyr Pharma, Inc. (NASDAQ:ATYR) from $9 to $17 while keeping a Buy rating. This decision comes ahead of the Phase 3 trial results for aTyr Pharma, Inc.’s (NASDAQ:ATYR) lead candidate, […] Sep 8, 2025 - $ATYR
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation Committee of aTyr’s Board of Directors has granted three employees nonstatutory stock options to purchase an aggregate of 62,400 shares of aTyr’s common stock, each with an exercise price of $5.71 per Sep 5, 2025 - $ATYR
ATyr Pharma Rated as Overweight at Cantor Fitzgerald on Efzofitimod Expectations
aTyr Pharma, Inc. (NASDAQ:ATYR) is one of the top multibagger penny stocks to buy, according to analysts. On August 4, analysts at Cantor Fitzgerald reiterated an ‘Overweight’ rating on the stock. The positive stance comes as the company is poised to present the Phase 3 trial for Efzofitimod, an NRP2 modulator being tested for Pulmonary […] Aug 20, 2025 - $ATYR
High Growth US Tech Stocks To Watch In August 2025
As the Dow Jones Industrial Average touches an all-time high and the tech-heavy Nasdaq Composite experiences a slump, investors are closely monitoring Federal Reserve signals amid a busy earnings season. In this dynamic environment, identifying high growth tech stocks involves evaluating companies that demonstrate robust innovation and adaptability to market shifts. Aug 19, 2025 - $ATYR
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple